Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Actinium Pharmaceuticals to $27 from $26 and keeps an Overweight rating on the shares. Actinium has been one of the more-successful stories in the firm’s coverage universe over the last six months following a successful Phase 3 data readout related to the SIERRA trial for Iomab-B in relapsed/refractory acute myeloid leukemia and further data and a validating CRADA partnership with the NCI for Actimab-A for AML and other hematologic malignancies, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATNM:
- Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones
- Coya Therapeutics appoints Arun Swaminathan to chief business officer
- Actinium Pharmaceuticals to discuss results from Phase 3 trial of Iomab-B
- Actinium Pharmaceuticals announces ‘positive’ phase 3 SIERRA trial data in AML
- Actinium downgraded despite positive data at William Blair